Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Letrozole Treatment in Normal and GnRH Deficient Women
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00351416
- Locations
- 🇺🇸
Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts, United States
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT00338728
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Letrozole in the Treatment of Endometrial Cancer
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT00333086
- Locations
- 🇩🇪
Novartis Investigative Site, Heidelberg, Germany
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 83
- Registration Number
- NCT00332709
- Locations
- 🇩🇪
Novaertis Investigative Site, Hamein, Germany
🇩🇪Novartis Investigative Site, Witten, Germany
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 655
- Registration Number
- NCT00332852
- Locations
- 🇩🇪
Novartis Investigative Site, Wolfsburg, Germany
🇩🇪Schorndorf, Konstanz, Germany
🇩🇪Novartis Investigative site, Celle, Germany
Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00333047
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00330317
- Locations
- 🇬🇧
Novartis Investigative Site, West Smithfield, United Kingdom
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00329940
- Locations
- 🇫🇷
Novartis Investigative Site, Saint Cloud, France
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10273
- Registration Number
- NCT00310180
- Locations
- 🇺🇸
Saint Ann's Hospital, Westerville, Ohio, United States
🇨🇦McGill University Department of Oncology, Montreal, Quebec, Canada
🇨🇦CHUM-Hotel Dieu de Montreal, Montreal, Quebec, Canada
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 43
- Registration Number
- NCT00305825
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.